Done, Fin.

It's over, Nycomed bit off more than it could chew and Solvay's pharma unit will be sold to Abbott Labs for a cool $7.6 billion. Weird how nothing happens for more than 6 months and a flurry of activity over the past 3 weeks leads to a major buy out. I hope Abbott is happy with what they got, personally I like what Abbott brings to the table more than what Nycomed has to offer Read more here from the Solvay press release and from Bloomberg

Continuing the recent string of vaccine-related news, Johnson and Johnson came out of the woodwork and nabbed a large stake of Crucell (who was making headlines earlier this year with a potential universal type A flu vaccine). J&J continues to make some very strong moves, so it would be worth jumping on board with them while you still can.

Crucell's development pipeline has some pretty high aspirations including vaccines for Ebola and Marburg virus in addition to their interesting flu vaccine technology. Check it out here.

Read about the deal from Reuters